Cobenfy

Boerner
Favicon Fierce Pharma

BMS delays key Cobenfy, milvexian readouts amid Q2 beat

BMS lifted its full-year outlook after recording nearly $13 billion in Q2 revenue, which topped Wall Street’s consensus by 10.6%.
Angus Liu Jul 30, 2026 10:12am
Boerner
Favicon Fierce Pharma

Bristol Myers CEO pledges to 'cast a broad net' in dealmaking

Jan 12, 2026 4:28pm
Bristol Myers Squibb
Favicon Fierce Pharma

With site 'irregularities,' BMS delays key Cobenfy readout

Dec 3, 2025 10:14am
IPO initial public offering

MapLight goes public via $250M IPO to fund Cobenfy competitor

Oct 27, 2025 6:45am
3D Rendering futuristic robot technology development artificial intelligence

MapLight illuminates $262M IPO plans to fund Cobenfy competitor

Oct 7, 2025 6:30am
Boerner
Favicon Fierce Pharma

BMS touts commercial execution, reckons with clinical setbacks

Jul 31, 2025 11:10am